BGLC vs. TOI, CCM, PMD, MRAI, ATIP, BRTX, KDLY, ATPC, OTRK, and OPGN
Should you be buying BioNexus Gene Lab stock or one of its competitors? The main competitors of BioNexus Gene Lab include Oncology Institute (TOI), Concord Medical Services (CCM), Psychemedics (PMD), Marpai (MRAI), ATI Physical Therapy (ATIP), BioRestorative Therapies (BRTX), Kindly MD (KDLY), Agape ATP (ATPC), Ontrak (OTRK), and OpGen (OPGN). These companies are all part of the "healthcare" industry.
BioNexus Gene Lab vs.
BioNexus Gene Lab (NASDAQ:BGLC) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.
Oncology Institute has a consensus target price of $2.50, indicating a potential upside of 354.55%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts clearly believe Oncology Institute is more favorable than BioNexus Gene Lab.
In the previous week, BioNexus Gene Lab had 1 more articles in the media than Oncology Institute. MarketBeat recorded 1 mentions for BioNexus Gene Lab and 0 mentions for Oncology Institute. BioNexus Gene Lab's average media sentiment score of 0.01 beat Oncology Institute's score of -0.71 indicating that BioNexus Gene Lab is being referred to more favorably in the media.
BioNexus Gene Lab has a net margin of -10.17% compared to Oncology Institute's net margin of -17.63%. BioNexus Gene Lab's return on equity of -9.93% beat Oncology Institute's return on equity.
BioNexus Gene Lab has a beta of 5.59, indicating that its share price is 459% more volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500.
Oncology Institute received 4 more outperform votes than BioNexus Gene Lab when rated by MarketBeat users.
BioNexus Gene Lab has higher earnings, but lower revenue than Oncology Institute.
18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 2.0% of BioNexus Gene Lab shares are owned by insiders. Comparatively, 9.5% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
BioNexus Gene Lab beats Oncology Institute on 8 of the 15 factors compared between the two stocks.
Get BioNexus Gene Lab News Delivered to You Automatically
Sign up to receive the latest news and ratings for BGLC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioNexus Gene Lab Competitors List
Related Companies and Tools
This page (NASDAQ:BGLC) was last updated on 1/21/2025 by MarketBeat.com Staff
